Clinical Trial Update: Rivastigmine to Prevent Recurrence of Antimuscarinic Delirium [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial at Washington University is evaluating rivastigmine to prevent recurrence of antimuscarinic delirium due to anticholinergic toxicity; t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anticholinergic Toxicity

Drugs mentioned

• Rivastigmine (Rivastigmine)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Anticholinergic Toxicity | Phase 2 | Status: RECRUITING